LAG3-PD-1 Combo Overcome the Disadvantage of Drug Resistance
Although PD-1 blockade therapy has been promising in cancer treatment, only 4% (pancreatic cancer) to 70% (melanoma) of patients have a positive response to this blockade therapy, which is one of its important disadvantages. Therefore, it is important to seek out new targets for cancer immunotherapy...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.831407/full |
| _version_ | 1811334344728379392 |
|---|---|
| author | Yiming Wei Zhaoming Li |
| author_facet | Yiming Wei Zhaoming Li |
| author_sort | Yiming Wei |
| collection | DOAJ |
| description | Although PD-1 blockade therapy has been promising in cancer treatment, only 4% (pancreatic cancer) to 70% (melanoma) of patients have a positive response to this blockade therapy, which is one of its important disadvantages. Therefore, it is important to seek out new targets for cancer immunotherapy to improve the overall response rate in patients. Lymphocyte activation gene-3 (LAG-3), an immune checkpoint receptor, is mainly expressed in activated immune cells. LAG-3 maintains the body’s immune homeostasis under physiological conditions while mediating tumour immune escape. Several preclinical and clinical examinations have shown that LAG-3 blockade effectively alleviates the patient’s tolerance to PD-1 immune checkpoint inhibitors. Moreover, the combination of LAG-3 and PD-1 blockade has good clinical efficacy in cancers. Hence, synchronous LAG-3 and PD-1 inhibition may be a potential new strategy for tumour immunotherapy. |
| first_indexed | 2024-04-13T17:06:37Z |
| format | Article |
| id | doaj.art-e138fbde79c64a0496798424eb19f93e |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-13T17:06:37Z |
| publishDate | 2022-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-e138fbde79c64a0496798424eb19f93e2022-12-22T02:38:27ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-04-011210.3389/fonc.2022.831407831407LAG3-PD-1 Combo Overcome the Disadvantage of Drug ResistanceYiming WeiZhaoming LiAlthough PD-1 blockade therapy has been promising in cancer treatment, only 4% (pancreatic cancer) to 70% (melanoma) of patients have a positive response to this blockade therapy, which is one of its important disadvantages. Therefore, it is important to seek out new targets for cancer immunotherapy to improve the overall response rate in patients. Lymphocyte activation gene-3 (LAG-3), an immune checkpoint receptor, is mainly expressed in activated immune cells. LAG-3 maintains the body’s immune homeostasis under physiological conditions while mediating tumour immune escape. Several preclinical and clinical examinations have shown that LAG-3 blockade effectively alleviates the patient’s tolerance to PD-1 immune checkpoint inhibitors. Moreover, the combination of LAG-3 and PD-1 blockade has good clinical efficacy in cancers. Hence, synchronous LAG-3 and PD-1 inhibition may be a potential new strategy for tumour immunotherapy.https://www.frontiersin.org/articles/10.3389/fonc.2022.831407/fullLymphocyte Activation Gene-3 (LAG-3)immune checkpointdrug resistanceProgrammed Cell Death 1 (PD-1)immunotherapy |
| spellingShingle | Yiming Wei Zhaoming Li LAG3-PD-1 Combo Overcome the Disadvantage of Drug Resistance Frontiers in Oncology Lymphocyte Activation Gene-3 (LAG-3) immune checkpoint drug resistance Programmed Cell Death 1 (PD-1) immunotherapy |
| title | LAG3-PD-1 Combo Overcome the Disadvantage of Drug Resistance |
| title_full | LAG3-PD-1 Combo Overcome the Disadvantage of Drug Resistance |
| title_fullStr | LAG3-PD-1 Combo Overcome the Disadvantage of Drug Resistance |
| title_full_unstemmed | LAG3-PD-1 Combo Overcome the Disadvantage of Drug Resistance |
| title_short | LAG3-PD-1 Combo Overcome the Disadvantage of Drug Resistance |
| title_sort | lag3 pd 1 combo overcome the disadvantage of drug resistance |
| topic | Lymphocyte Activation Gene-3 (LAG-3) immune checkpoint drug resistance Programmed Cell Death 1 (PD-1) immunotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.831407/full |
| work_keys_str_mv | AT yimingwei lag3pd1comboovercomethedisadvantageofdrugresistance AT zhaomingli lag3pd1comboovercomethedisadvantageofdrugresistance |